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KEY FINDINGS 
Health care quality is largely unrelated 
to health care price 
Four of the five price-quality correlation 
coefficients were between –0.45 and 
0.00, suggesting a negative or null rela-
tionship between price and quality. 
Prices for health care services are gen-
erally related, while quality measures 
are not 
All ten price correlations were larger 
than 0.50 and nine of the ten quality 
measure correlations were less than 
0.35, suggesting states may be character-
ized as high or low priced, but the level 
of quality may vary within a state. 
The Price-Quality Paradox in 
Health Care  
the quality will be the same; and, thus, are 
not correlated. 
We calculated the correlation between the 
state-level quality measures and prices to 
address the question “is higher quality asso-
ciated with higher prices?” The correlation 
coefficients are presented in Table 1. A posi-
tive correlation implies higher quality 
measures occur where prices are higher. A 
negative correlation implies the quality 
measures are relatively lower where prices 
are higher and higher quality occurs where 
there are lower prices. Furthermore, the 
magnitude of the correlation coefficient sug-
gests how strong the relationship is between 
price and quality. A correlation of 1.00 im-
plies for every unit increase in price, quality 
increases proportionally (a –1.00 correlation 
implies price and quality move in opposite 
directions). On the other hand, a correlation 
coefficient of 0.00 implies there is no con-
sistent relationship between the two 
measures.  
The results suggest that higher prices are 
not indicative of better quality of care. Of the 
five price-quality correlations, only hemoglo-
bin A1C test had a weakly positive correla-
The recent push for greater transpar-
ency in health care has often focused 
on making prices more accessible and 
useful to all health care stakehold-
ers—consumers, payers, employers, 
etc. Yet, with only price information, 
stakeholders have no way to deter-
mine if paying a higher price is war-
ranted. Public information about the 
quality of health care services needs to 
be provided alongside prices if health 
care transparency efforts have any 
chance of reducing costs while im-
proving health outcomes. This data 
brief examines how the quality of 
health care services is related to pric-
es. 
The Health Care Cost Institute (HCCI) 
calculated quality of care measures 
with the same claims data used to esti-
mate the average prices of common 
health care services, publically availa-
ble on guroo.com. Like the price esti-
mates, these quality measures are re-
ported at the local, state, and national 
levels. 
Quality and price of five measures are 
discussed in this brief; one related to 
asthma (asthma evaluation), two re-
lated diabetes (diabetes evaluation 
and hemoglobin A1C test), and two 
related to hypertension (hypertension 
evaluation and creatinine test). Higher 
measure values imply higher quality of 
care. (See “Data and Methods” for ad-
ditional details.) 
Table 1 presents the mean and stand-
ard deviation of the five state-level  
quality measures and their compara-
ble price estimates, which were re-
portable for 42 states and D.C.1 The 
results show that there are significant 
differences in the provision of recom-
mended care across quality measures. 
While nearly every diabetes patient 
receives an annual evaluation (97%), 
only about half of the individuals with 
asthma have an annual physician visit 
related to their condition.  
There is no consistent relationship 
between quality measures and prices 
Figures 1-5 are scatter plots showing 
the relationship between the state-
level quality and relative price 
measures. Quality is measured along 
the horizontal axis with quality meas-
ure values increasing left to right. The 
vertical axis is a normalized price 
measure, calculated as the ratio of 
each state-level price divided by the 
national average price for the same 
service. Thus, the vertical axis shows 
to what extent a state-level price is 
above (>1.0) or below (<1.0) the na-
tional average price.  
The red dot on each graph represents 
the intersection of the national aver-
age price and national average quality 
level for each measure. Among the 
negatively correlated measures, asth-
ma and hypertension evaluation, most 
of the state-level points are in the up-
per left and lower right quadrants of 
the graph. This indicates higher quali-
ty in states with lower relative prices 
and lower quality in states with higher 
relative prices.  The hemoglobin eval-
uation measure graph depicts an op-
posite distribution—higher quality 
where there are higher prices. The 
creatinine measure points are scat-
tered evenly across the graph, sug-
gesting no relationship between price 
and quality. The points on the diabe-
tes evaluation measure graph are 
highly concentrated around the quali-
ty average, but have a wide range of 
prices. This suggests that no matter 
the price of the diabetes evaluation, 
Higher prices for medical services are not always indicative of higher 
quality of care  
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tion of 0.18. Creatinine tests had a weak 
but negative correlation coefficient of -
0.11. The quality measures for asthma 
evaluation and hypertension evaluation 
were both negatively correlated with 
their corresponding prices and the mag-
nitudes were moderately high; -0.37 and 
-0.45 respectively. No relationship be-
tween diabetes evaluation quality and 
price was found—the correlation was 
0.00.  
A higher quality measure for one health 
care service does not guarantee higher 
quality for another 
We also tested the correlation between 
the five quality measures, the resulting 
matrix of correlations is presented in 
Table 2. Positive correlations between 
the different measures suggests similar 
patterns in quality across different ser-
vices. While one would expect a highly 
positive correlation between the ser-
vices related to the same underlying 
condition, the results did not support 
this expectation. Hemoglobin testing 
and diabetes evaluation were only mod-
erately correlated (0.34) and the creati-
nine testing-hypertension evaluation 
correlation was even weaker at 0.16.  
There was a strong, positive correlation 
between hemoglobin A1C testing and 
creatinine testing (0.84). Hypertension 
evaluation was moderately correlated 
with diabetes (0.34) and asthma (0.37) 
evaluations. The remaining quality pair-
ings had weak to no correlation.  
Higher price levels for one health care 
serivce suggest prices may be higher 
for other services 
Finally, we examined the relationship 
between the prices of the corresponding 
medical procedures. Unlike the quality 
measure relationships, all of the price 
correlations were positive and greater 
than 0.50 (Table 3). The results suggest 
that health care prices are related even 
where prices and quality for the same 
services are not. The correlation of dia-
betes evaluation and hemoglobin A1C 
testing prices, both of which are related 
to treatment for diabetes, was 0.89. Sim-
ilarly, the correlation of prices for treat-
ments of hypertension, hypertension 
evaluation and creatinine testing, was 
0.70.  
Among all 10 state-level price-to-price 
pairings, the lowest correlation (0.55) 
was among two different categories of 
health care services (creatinine testing 
and asthma evaluation). However, the 
nearly perfect correlation of 0.97, was 
also between different service catego-
ries (asthma and diabetes evaluations).  
Conclusion 
Although stakeholders need more  
information about the costs of health 
care serivces, they are limited in how 
they can use that information without 
knowing what to expect for a given 
price. The results of this evaluation of 
the relationship between state-level 
quality and price measures demonstrate 
how price alone may not be sufficent for 
identifing quality. In some cases, it 
appears that higher prices are acutally 
associated with lower quality. If policy 
makers and health care industry leaders 
expect transparency efforts to have real 
impacts on the health care system, 
making quality information more 
accessible and useable by stakeholders 
is also necessary.  
Limitations 
Both the price and quality measures 
used in this analysis were calculated at a 
state level and may differ from a partic-
ular provider’s prices or quality. The 
measures reflect the average for the 
state allowing for nationwide analysis. 
Additionally, the quality measures were 
calculated from claims data and reflect a 
measure of quality of care based on 
whether recommended services were 
provided. A provider’s treatment may 
differ from the recommended care for 
many reasons and there are numerous 
other ways to evaluate quality. The qual-
ity measures do provide a sense of 
whether particular patient populations 
are receiving the types of services asso-
ciated with improved outcomes.  
Data and Methods 
HCCI's data set includes de-identified, 
HIPPA compliant health insurance 
claims from multiple national health 
insurers, representing over 50 million 
covered lives. The membership and 
claims data include details such as zip 
codes, diagnostic codes, procedure 
codes, actual amounts paid by the 
insurer as well as the  copayments, 
deductibles, and coinsurance paid by the 
insured. Both individual and employer 
sponsored insurance claims were 
included in the analyses.  
The quality measures were calculated 
with person-level claims data using 
Symmetry EBM Connect software 
version 9.0.2 The person-level results 
were aggregated to local, state, and 
national levels for reporting and 
analysis. The quality measures assess 
whether patients with a specific 
diagnosis received recommended health 
care services, which are known to 
improve health outcomes. The measures 
are reported as the percentage of 
patients who received the 
recommended care.  
The price measures included in the 
analysis were the most comparable to 
the services for which quality measures 
were calculated.  For additional details 
on the average price estimates and 
reporting requirements see guroo.com.3  
Endnotes 
1. HCCI data are insufficient for 
reporting prices in Alabama, Idaho, 
Hawaii, Michigan, Montana, South 
Dakota, Vermont, and Wyoming.  
2. Additional details are available at: 
https://www.optum.com/
government/fed/analytics-hit/
population-analytics/measuring-value
-understanding-costs/symmetry-ebm-
connect.html. 
3. Additional details are available at: http://
www.guroo.com/#!terms-and-
conditions. 
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Table 1. Summary Statistics and Quality-Price Correlations 
 Quality Measure Description 
Price Measure  
Description 
Price 
Mean 
(SD) 
Quality 
Mean 
(SD) 
Quality—Price 
Correlation 
Asthma  
Evaluation 
People with asthma should have regular doctor visits 
to monitor and review control of their asthma, treat-
ment plan, and medications. This measure reports 
the percentage of people with asthma who had an 
office visit for asthma care within the last 6 months. 
For this measure, a higher score is better.  
Four visits with a primary care 
physician to evaluate your 
asthma and determine the 
best course of treatment 
$734.47 
(190.14) 
54.85 
(1.83) 
-0.37 
Diabetes  
Evaluation 
People with diabetes should receive regular medical 
care. At a minimum, an annual doctor visit is recom-
mended. This measure reports the percentage of 
people with diabetes who had at least 1 visit during 
the last 12 months. For this measure, a higher score 
is better.  
Two visits with a specialist for 
a detailed evaluation and 
treatment of your diabetes 
$353.65 
(99.60) 
97.57 
(0.88) 
0.00 
Hemoglobin 
A1c Test 
Hemoglobin A1c (HbA1c) testing should be performed 
routinely for all people with diabetes. HbA1c testing is 
recommended at least 2 times per year. This meas-
ure reports the percentage of people who had at least 
1 HbA1C test in the last 6 months. For this measure, 
a higher score is better.  
HbA1c test is a blood test 
used to diagnose or check for 
diabetes 
$183.91 
(62.53) 
79.70 
(2.73) 
0.18 
Hypertension 
Evaluation 
People being treated for hypertension should have a 
minimum of one doctor visit per year to assess their 
adherence to the treatment and changes in target 
organ function. This measure reports the percentage 
of people with hypertension who had a visit for a 
hypertension assessment within the last 12 months. 
For this measure, a higher score is better.  
One visit with a primary care 
physician to evaluate your 
blood pressure and determine 
the best course of treatment 
$17.30 
(9.53) 
58.17 
(5.54) 
-0.45 
Creatinine 
Test 
At least one serum creatinine test per year is recom-
mended for people being treated for hypertension. 
This measure reports the percentage of people with 
hypertension that had a serum creatinine test in last 
12 months. For this measure, a higher score is better.  
Creatinine test to check the 
level of creatinine in the blood 
system 
$13.35 
(5.49) 
68.31 
(3.75) 
-0.11 
Source: HCCI, 2016. 
Notes: All reported correlations are Pearson product moment correlation coefficients, which measure the linear correlation between 
variables. The standard deviation is listed in parentheses.  
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Source: HCCI, 2016. 
Notes: All reported correlations are Pearson product moment correlation coefficients, which measure the linear correlation between 
variables.  
Table 2. Quality to Quality Correlation  
  Asthma Diabetes Hemoglobin  Hypertension Creatinine 
Asthma Evaluation 1.00         
Diabetes Evaluation 0.05 1.00       
Hemoglobin A1c Test  -0.03 0.35 1.00     
Hypertension Evaluation 0.37 0.34  -0.03 1.00   
Creatinine Test -0.02 0.21 0.84 0.16 1.00 
Table 3. Price to Price Correlation  
  Asthma Diabetes Hemoglobin  Hypertension Creatinine 
Asthma Evaluation 1.00         
Diabetes Evaluation 0.97 1.00       
Hemoglobin A1c Test  0.81  0.89  1.00     
Hypertension Evaluation 0.90 0.97 0.92 1.00   
Creatinine Test 0.55 0.62 0.64 0.70 1.00 
Source: HCCI, 2016. 
Notes: All reported correlations are Pearson product moment correlation coefficients, which measure the linear correlation between 
variables.  
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Figure 2. Diabetes Evaluation Price—Quality Relationship (n=43) 
Source: HCCI, 2016. 
Source: HCCI, 2016. 
Figure 1. Asthma Evaluation Price—Quality Relationship (n=43) 
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Figure 4. Hypertension Evaluation Price—Quality Relationship (n=43) 
Source: HCCI, 2016. 
Source: HCCI, 2016. 
Figure 3. Hemoglobin A1C Price—Quality Relationship (n=43) 
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Source: HCCI, 2016. 
Figure 5. Creatinine Test Price—Quality Relationship (n=43) 
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